Breast cancer subtypes and response to systemic treatment after whole‐brain radiotherapy in patients with brain metastases

The aim of this study was to assess the role of systemic treatment after whole‐brain radiotherapy (WBRT) in immunohistochemically defined biological subsets of breast cancer patients with brain metastases.

[1]  M. Murawska,et al.  The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. , 2010, International journal of radiation oncology, biology, physics.

[2]  K. Pogoda,et al.  Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  D. Kondziolka,et al.  The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[4]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[6]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[7]  K. Aldape,et al.  Defining prognosis for women with breast cancer and CNS metastases by HER2 status. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  K. Hopkins,et al.  Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer , 2008, American journal of clinical oncology.

[9]  J. Henson,et al.  Survival in patients with brain metastases from breast cancer , 2008, Cancer.

[10]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Tae Hyun Kim,et al.  Breast cancer subtypes and survival in patients with brain metastases , 2008, Breast Cancer Research.

[12]  L. Deangelis,et al.  Capecitabine Therapy of Central Nervous System Metastases from Breast Cancer , 2007, Journal of Neuro-Oncology.

[13]  L. Crinò,et al.  Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. , 2007, The oncologist.

[14]  G. Steger,et al.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer , 2007, Journal of Neuro-Oncology.

[15]  M. Murawska,et al.  Breast cancer leptomeningeal metastasis—the role of multimodality treatment , 2007, Journal of Neuro-Oncology.

[16]  Kristine Broglio,et al.  Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma , 2006, Cancer.

[17]  J. Raizer,et al.  Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial , 2006, Journal of Neuro-Oncology.

[18]  Takako Yamada,et al.  Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. , 2006, Breast.

[19]  F. Cognetti,et al.  Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow? , 2006, Cancer investigation.

[20]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[21]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[23]  D. Antonadou,et al.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Arnold,et al.  Diagnosis and management of brain metastases. , 2001, Hematology/oncology clinics of North America.

[25]  Michael L. Wang,et al.  Capecitabine for 5‐Fluorouracil‐Resistant Brain Metastases From Breast Cancer , 2001, American journal of clinical oncology.

[26]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[27]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[28]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[29]  S. Dahrouge,et al.  Response of brain metastases from breast cancer to megestrol acetate: A case report , 2005, Journal of Neuro-Oncology.

[30]  J. Wolchok,et al.  Systemic chemotherapy. , 2000, Clinics in plastic surgery.

[31]  C. Boni,et al.  Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. , 1990, Cancer investigation.